Boston Scientific (BSX) Tops Q2 EPS by 4c; offers guidance
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $43.34 -0.48%
EPS Growth %: +5.3%
Financial Fact:
Operating expenses: 1.16B
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +5.3%
Financial Fact:
Operating expenses: 1.16B
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.62, $0.04 better than the analyst estimate of $0.58. Revenue for the quarter came in at $4.12 billion versus the consensus estimate of $4.02 billion.
GUIDANCE:
Boston Scientific sees Q3 2024 EPS of $0.57-$0.59, versus the consensus of $0.57.
Boston Scientific sees FY2024 EPS of $2.38-$2.42, versus the consensus of $2.33.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Nscale files for IPO, seeks NYSE listing under ticker NSCL
- Teva shares Phase 3 data on once-monthly schizophrenia injection
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
